Share price · ALMS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALMS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 1 Sep 2026-56.6%
- 11 Aug 2026-7.8%
- 3 Aug 2026-7.5%
Nothing announced by ALMS that day or the session before.
- 30 Jul 2026+9.7%
Nothing announced by ALMS that day or the session before.
- 12 Jun 2026+15.6%
Nothing announced by ALMS that day or the session before.
- 6 Jan 2026+95.3%
- 5 Dec 2025+34.0%
Nothing announced by ALMS that day or the session before.
- 18 Nov 2025+15.0%
Nothing announced by ALMS that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALMS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | TYK2Small molecule | PsoriasisSystemic Lupus Erythematosus | |
| Phase 1 | TYK2Small molecule | Parkinson's DiseaseMultiple Sclerosis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (1)
November 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.9M | $81M | $59M+ $374M short-term inv. | $95M-$80M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.7M | $85M | $65M+ $439M short-term inv. | $142M-$82M operating cash flow | report ↗ |
| 2026-Q1 | $1.7M | $82M | $65M+ $506M short-term inv. | $93M-$87M operating cash flow | report ↗ |
| 2025-Q3 | $2.1M | $98M | $67M+ $312M short-term inv. | $111M-$111M operating cash flow | report ↗ |
| 2025-Q2 | $2.7M | $109M | $154M+ $335M short-term inv. | —-$106M operating cash flow | report ↗ |
| 2025-Q1 | $17M | $97M | $130M+ $80M short-term inv. | $99M-$80M operating cash flow | report ↗ |
| 2024-Q3 | — | $88M | $214M+ $148M short-term inv. | $93M-$84M operating cash flow | report ↗ |
| 2024-Q2 | — | $49M | $156M+ $54M short-term inv. | $57M-$52M operating cash flow | report ↗ |
| 2024-Q1 | — | $42M | $113M | $50M-$44M operating cash flow | report ↗ |
| 2023-Q3 | — | $38M | $55M | $43M-$33M operating cash flow | report ↗ |
| 2023-Q2 | — | $33M | $81M | $36M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $24M | $386M | $91M+ $219M short-term inv. | $61M-$370M operating cash flow | report ↗ |
Alumis reported FY2025 revenue of $24.05M, with no prior-year revenue figure disclosed, and R&D spend of $386M, up 45.4% YoY from $265.55M. Cash and equivalents stood at $91.05M, while total cash, cash equivalents and marketable securities were $308.5M as of December 31, 2025. The company reported a net loss of $243.32M, with quarterly net burn of $243.33M.
Management guided that existing cash, cash equivalents and marketable securities, plus approximately $324.4M in net proceeds from the January 2026 public offering, are expected to fund operations into the fourth quarter of 2027. Pipeline highlights included positive Phase 3 ONWARD1 and ONWARD2 topline results in moderate-to-severe plaque psoriasis, a planned NDA submission in 2H 2026, potentially pivotal Phase 2b SLE topline data anticipated in 3Q 2026, and additional Phase 3 data at AAD 2026. The company also completed an upsized public offering raising approximately $345.1M in gross proceeds in January 2026, with updates expected on its TYK2 franchise strategy in 2Q 2026, lonigutamab strategic review in 1H 2026, and a Phase 1 trial start for its next candidate in 2H 2026.
Insider transactions
Open-market activity, trailing 12 months: 23 purchases ($48.5M), 15 sales ($1.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Bradley Mark Christopher · Chief Development Officer | Open-market sale | 623 | $6.52 | $4K | Form 4 |
| 2026-11-02 | Drappa Jorn · Chief Medical Officer | Open-market sale | 593 | $6.52 | $4K | Form 4 |
| 2026-11-02 | Goldstein David M · Chief Scientific Officer | Open-market sale | 629 | $6.52 | $4K | Form 4 |
| 2026-11-02 | Hardiman Roy C. · Chief Business & Strategy Ofcr | Open-market sale | 652 | $6.52 | $4K | Form 4 |
| 2026-11-02 | Pangali Sanam · Chief Legal Officer | Open-market sale | 332 | $6.52 | $2K | Form 4 |
| 2026-11-02 | Schroer John R. · Chief Financial Officer | Open-market sale | 794 | $6.52 | $5K | Form 4 |
| 2026-09-08 | AKKARAJU SRINIVAS · director | Open-market sale | 48,066 | $10.55 | $507K | Form 4 |
| 2026-09-08 | AKKARAJU SRINIVAS · director | Open-market sale | 48,065 | $10.55 | $507K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 196 reporting institutions held 99.7M shares ($2.1B, 78.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 7,170,868 | $158.0M |
| 2 | Deep Track Capital, LP | 6,772,595 | $149.2M |
| 3 | SAMSARA BIOCAPITAL, LLC | 6,345,219 | $139.8M |
| 4 | Foresite Capital Management V, LLC | 5,896,995 | $129.9M |
| 5 | venBio Partners LLC | 4,528,408 | $99.8M |
| 6 | Foresite Capital Management VI LLC | 4,247,670 | $93.6M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4,032,266 | $88.8M |
| 8 | Cormorant Asset Management, LP | 3,949,241 | $87.0M |
| 9 | Nextech Invest, Ltd. | 3,540,998 | $78.0M |
| 10 | Saturn V Capital Management LP | 3,202,075 | $70.5M |
| 11 | UBS Group AG | 3,054,865 | $67.3M |
| 12 | Octagon Capital Advisors LP | 2,830,700 | $62.4M |
| 13 | MPM BIOIMPACT LLC | 2,386,529 | $52.6M |
| 14 | JANUS HENDERSON GROUP PLC | 2,124,408 | $46.8M |
| 15 | BAKER BROS. ADVISORS LP | 2,012,500 | $44.3M |